Allergies News and Research

Latest Allergies News and Research

XTIO2 presents XTI 360 ANTI-GERM SYSTEM to 83rd Academy Award-nominees

XTIO2 INC. (XTI) presented the 83rd Academy® Award-nominees with the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM, consisting of XTI 360™ Nanocoating and XTI™ Nano-Facemask. It is the world's most effective preventive measure and the best defense against germs transmitted via air and contact surfaces.

15 Mar 2011

Research: Used instrument can pose dangerous health risk in children

Research has shown that playing a musical instrument can help nourish, cultivate, and increase intelligence in children, but playing a used instrument also can pose a potentially dangerous health risk.

15 Mar 2011

Scientists show how E. coli strain causes infection in individuals

Scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have shown how the O157:H7 strain of Escherichia coli causes infection and thrives by manipulating the host immune response.

15 Mar 2011

Peanut allergy has a genetic link: Study

A new study suggests that children with a certain gene defect are more likely to develop a peanut allergy. They studied the effect of changes in the gene filaggrin, which helps the skin block out allergens. They noted what has been seen before – the changes in the gene reduce the effectiveness of the barrier, increasing the risk for eczema and asthma.

14 Mar 2011

NIH awards InDevR $3 million Phase II SBIR grant for influenza-related research

InDevR announced today that it has been awarded a Phase II Small Business Innovation Research grant from the National Institutes of Health in the amount of $3 million over the next 3 years.

11 Mar 2011

Researchers uncover new disease mechanism in patients with CGD

Infection researchers at Umeå University have uncovered a new disease mechanism in patients with Chronic Granulomatous Disease in an international clinical collaboration with the Children's Hospital in Zurich.

11 Mar 2011

New discovery: GPCR family of proteins can recognize and respond to wide array of signals

Scientists from The Scripps Research Institute have determined a new structure from a medically important superfamily of proteins. The structure should help instruct the design of a new kind of therapeutics for conditions ranging from Parkinson's disease to inflammation.

11 Mar 2011

Iron deficiency during pregnancy may directly impact infant breathing health

Need a reason to take your iron supplements? Iron deficiency during pregnancy may directly impact infant and childhood breathing health according to a study recently published in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

10 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Ohio officials seek federal permission for use of propoxur to halt bedbug infestations

Mom's comforting tuck-them-in-words - "Sleep tight, don't let the bedbugs bite"- is becoming an impossible dream for millions of people as the world experiences a resurgence of an ancient scourge that is fostering human misery, financial burdens and the risk of exposure to potentially toxic materials. That's the message from the cover story of the current edition of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

10 Mar 2011

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced today that the US Food and Drug Administration (FDA) has accepted its Extended Release Carbinoxamine Oral Suspension NDA for the treatment of allergies in kids two years and older. If approved, Tris Pharma's Extended Release Suspension will provide an alternative to the currently available immediate release formulations.

10 Mar 2011

Immunologists identify key cell component that triggers allergic responses to cat dander

A breakthrough by scientists at The University of Nottingham could provide hope for any allergy sufferers who have ever had to choose between their health and their household pet.

10 Mar 2011

MD Solarsciences launches new sunscreen lotion at 2011 AAD meeting

A year after its launch, the first dermatologist-driven company dedicated to primary skin cancer protection and prevention introduced its newest solar protection product -- a much-anticipated tinted mineral gel sunscreen – at the 2011 AAD meeting in New Orleans.

9 Mar 2011

Allergy Asthma Research Institute, Forest Labs join SAFE-BioPharma

In a move to improve efficiency by reducing paper in their respective operations, Forest Laboratories and the Allergy Asthma Research Institute have joined SAFE-BioPharma Association. They now have access to the SAFE-BioPharma® digital identity and signature standard, used throughout the biopharmaceutical industry to verify and manage digital identities involved in electronic transactions and to apply digital signatures to electronic documents.

9 Mar 2011

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

An advisory committee recommended today that the Food and Drug Administration (FDA) approve QAB149 (indacaterol) 75 mcg in the US as a once-daily long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

9 Mar 2011

$100 million in grants for medical research announced

More than $100 million in grants was announced this Tuesday for an ambitious research project that will try to find what makes cancer so hard to beat. This project received $21.3 million from the National Health and Medical Research Council grants.

8 Mar 2011

Mississippi researchers work on drug discovey for poison ivy skin rash

Each year nearly 50 million Americans develop an annoying skin rash after coming in contact with poison ivy. But University of Mississippi researchers are working on a pharmaceutical product to rein in the allergic reaction in people already sensitive to the plants and prevent it altogether in those who aren't.

8 Mar 2011

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on their level of CD4+ T-cells.

8 Mar 2011

FDA's action impacts Elite pharma drugs

Elite Pharmaceuticals, Inc. advises that the US Food and Drug Administration announced that it intends to remove approximately 500 cough/cold and allergy related products from the U.S. market.

7 Mar 2011

iPrEx update, bone mineral density study highlighted at day three of 18th CROI

The 18th Conference on Retroviruses and Opportunistic Infections is being held at the Hynes Convention Center in Boston from February 27 through March 2. Day three of this major HIV/AIDS research conference included the following selected presentations from scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

5 Mar 2011